510(k) Report

510(k) · Cleared

Cleared

Bonalive Orthopedics granules

K231528510(k) TraditionalCleared Jul 11, 202346-day reviewClass II21 CFR 888.3045

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bonalive Biomaterials, Ltd. · MQV Filler, Bone Void, Calcium Compound

Cleared on Jul 11, 2023 as substantially equivalent to K191274 (Bonalive Biomaterials, Ltd., 2019) after a 46-day review. Its family tree reaches back 5 generations to 1996. 6 later devices descend from it.

Decided
Jul 11, 2023
Review
46 days
Class
Class II
Product code
MQV
Recalls
None
Predicates
1

Its longest line of descent runs back 5 generations to K960978 (1996). 6 ancestors in all. 6 later devices descend from it, 4 citing it directly.

  1. Root · 5 generations backK960978 Wright Plaster of Paris Pellets (Subject to Revision)Wrightmedicaltechnologyinc · 1996
  2. 4 generations backK980817 Pro Osteon Implant 500R Resorbable Bone Graft Substitute Model…Interpore Intl. · 1998
  3. 3 generations backK021336 Novabone-Resorbable Bone Graft SubstituteNovabone Products, LLC · 2002
  4. 2 generations backK071199 Bonalive GranulesVivoxid, Ltd. · 2008
  5. 1 generation backK191274 BonAlive GranulesBonalive Biomaterials, Ltd. · 2019
  6. This deviceK231528 Bonalive Orthopedics granulesBonalive Biomaterials, Ltd. · 2023
  7. Descendant · cites it directly · 3 of its ownK234013 Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc. · 2024
  8. Descendant · 2 generations on · 2 of its ownK242372 Mg OSTEOREVIVE™, Mg OSTEOCRETE™Bone Solutions, Inc. · 2024
  9. Descendant · cites it directly · 1 of its ownK251522 Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc. · 2025
  10. Descendant · 2 generations on · 0 of its ownK262230 Mg OSTEOREVIVE™;Mg OSTEOCRETE™Bone Solutions, Inc. · 2026
  11. Descendant · cites it directly · 0 of its ownK242782 GlassBone GranulesNoraker · 2024

Showing 5 of 6 descendants. See all descendants

Descendants cleared per year

2024: 42025: 12026: 1
2024high 4 (2024) · low 1 (2025)2026

Most influential descendants

Showing 5 of 6 · See all
  • K234013Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc. · 2024 · cites it directly3descendants
  • K242372Mg OSTEOREVIVE™, Mg OSTEOCRETE™Bone Solutions, Inc. · 2024 · 2 generations on2descendants
  • K251522Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc. · 2025 · cites it directly1descendant
  • K262230Mg OSTEOREVIVE™;Mg OSTEOCRETE™Bone Solutions, Inc. · 2026 · 2 generations on0descendants
  • K242782GlassBone GranulesNoraker · 2024 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−5K960978Wright Plaster of Paris Pellets (Subject to Revision)Wrightmedicaltechnologyinc1996—
−4K980817Pro Osteon Implant 500R Resorbable Bone Graft Substitute Model Numbers 5RG05…Interpore Intl.1998—
−3K021336Novabone-Resorbable Bone Graft SubstituteNovabone Products, LLC2002—
−2K071199Bonalive GranulesVivoxid, Ltd.2008—
−1K191274BonAlive GranulesBonalive Biomaterials, Ltd.2019—
0 (this device)K231528Bonalive Orthopedics granulesBonalive Biomaterials, Ltd.2023—
+1K234013Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc.2024—
+2K242372Mg OSTEOREVIVE™, Mg OSTEOCRETE™Bone Solutions, Inc.2024—
+1K251522Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc.2025—
+2K262230Mg OSTEOREVIVE™;Mg OSTEOCRETE™Bone Solutions, Inc.2026—
+1K242782GlassBone GranulesNoraker2024—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199710

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202440
202510
202610
FIG. 1 — Lineage of K231528, 1996–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MQV? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MQV device

  1. #1 K232315 Catalyst Bone Void Fillerscore 25.2 · 25 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K191274BonAlive Granules
Summary page 4
…Review Panel: Orthopedic Reason for Submission: Labeling Change Prior Related Submissions: K191274 Multiple Devices: None 5. Legally Marketed Predicate Device(s) Predicate: K191274 Bonalive® gra…
Bonalive Biomaterials, Ltd.2019—
†K113871Pro-Dense Bone Graft SubstituteWrightmedicaltechnologyinc2013—

What descends from it? (6)

4 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K234013Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc.20243
K251522Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc.20251
K242782GlassBone GranulesNoraker20240
K243526MONTAGE Settable, Resorbable Bone Putty MONTAGE-QS Settable, Resorbable Bone Putty…Orthocon, Inc.20240

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 27 years and passes through 5 companies; a new generation was cleared every 3.9 years on median.
  • None of the 6 ancestors has a recall.
  • Of its descendants, K234013 (Bone Solutions, Inc., 2024) has gone furthest, with 3 descendants of its own.

How does its category compare?

All MQV devices

MQV Filler, Bone Void, Calcium Compound: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · MQV

14in 2025

2007: 352008: 322009: 232010: 172011: 162012: 92013: 122014: 202015: 182016: 82017: 172018: 232019: 132020: 152021: 82022: 92023: 212024: 282025: 142026 (partial year): 5
2007high 35 (2007) · low 8 (2016)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MQV

57in 2025

2007: 144 days median2008: 102 days median2009: 180 days median2010: 147 days median2011: 92 days median2012: 107 days median2013: 197 days median2014: 153 days median2015: 184 days median2016: 214 days median2017: 124 days median2018: 124 days median2019: 90 days median2020: 132 days median2021: 88 days median2022: 118 days median2023: 74 days median2024: 55 days median2025: 57 days median2026 (partial year): 96 days median
2007high 214 (2016) · low 55 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MQV

1in 2025

2007: 52008: 32009: 12011: 62012: 32013: 22016: 12017: 12018: 22020: 12023: 32024: 22025: 12026 (partial year): 4
2007high 6 (2011) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MQV

57in 2025

2007: 672008: 712009: 812010: 682011: 1142012: 1492013: 2232014: 1112015: 1252016: 1062017: 1072018: 862019: 652020: 1262021: 1012022: 472023: 1202024: 682025: 57
2007high 223 (2013) · low 47 (2022)2025

MAUDE reports naming product code MQV, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200735144567
200832102371
200923180181
201017147068
201116926114
201291073149
2013121972223
2014201530111
2015181840125
201682141106
2017171241107
201823124286
20191390065
2020151321126
20218880101
20229118047
202321743120
20242855268
20251457157
20265964—

What is it indicated for?

Bonalive® Orthopedics granules is an implant intended to fill bony voids or gaps of the skeletal system (i.e., extremities and pelvis). These osseous defects may be the result of benign bone cysts and tumors (in adults and pediatric patients ≥ 6 years old), are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. Bonalive® Orthopedics granules resorbs and is replaced with bone during the healing process.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K231528: Bonalive Orthopedics granules.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K231528

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026